Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
ASCs inhibit the production of Th17-associated cytokines, such as IL-17A and TNF-α, and minimize the psoriatic skin changes induced by IMQ. The administration of ASCs inhibits systemic IMQ-induced inflammation. In this study, we have proven the potential clinical application of allogeneic or autogenic ASCs for the treatment of psoriasis through a process that differs considerably from existing biological therapies.
|